Navigation Links
Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1

ients."

About Omega DUROS Therapy

Omega DUROS therapy is being developed to improve the treatment of HCV by offering a more convenient and potentially safer and more effective treatment. Omega DUROS therapy is designed to deliver a continuous and consistent dose of omega interferon for three months via the implantable DUROS device, a drug delivery technology developed by ALZA Corporation, and licensed to Intarcia for use in certain broad fields. Another product incorporating the DUROS technology has already approved by the FDA for the palliative treatment of prostate cancer. Intarcia is also leveraging the DUROS technology in evaluating other drug development opportunities. The most advanced of these is focused on the delivery of GLP-1 and a GLP-1 analog with the DUROS device for the treatment of type 2 diabetes.

About Intarcia

Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapeutics for patients with chronic diseases in which there are significant unmet medical needs. Intarcia's drug development expertise and competitive edge are complemented by its ability to stabilize macromolecules and to deliver them in a constant and consistent manner via the proprietary DUROS drug delivery platform. The initial programs that Intarcia is pursuing are in hepatitis C and type 2 diabetes.

About Hepatitis C

Hepatitis C is a major global public health problem. According to the World Health Organization, more than 170 million people worldwide are chronically infected with HCV, and three to four million new HCV infections occur annually. The U.S. Centers for Disease Control and Prevention has estimated that in the United States approximately 3.4 million people are chronically infected with HCV and approximately 25,000 new patients are infected each year. It is estimated that 10,000 to 12,000 patients die annually in the United States from complications resulting from HCV infection. The current standard of care for tr
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Intarcia Therapeutics Announces Presentation of Final Results From a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics

Post Your Comments:
(Date:11/24/2009)...wswire/-- ,, WHAT:RomHoubens,aBelgianmanthought...wasactuallyfullyconsciousandawakeduringthattimeand...oxEyeMaxwasfeaturedinthesegmenttoillustratehowpeop...communication. ,, WHEN:GoodMorningAmerica-- Tue...ch.com ,, WHO:RomHoubenswasanengineeringstu...
(Date:11/24/2009)...Newswire-FirstCall/--QuestDiagnosticsIncorporated(...esting,informationandservices,announcedthatitissch...ConferenceinNewYorkCity.Thepresentationisscheduled...,, Duringtheconference,thecompanywillreaffirmit...tingincometoexceed18%ofrevenues,anddilutedearnings...
(Date:11/24/2009)...wire-FirstCall/--AnadysPharmaceuticals,Inc.(Nasdaq...nualPiperJaffrayHealthcareConferenceonTuesday,Dece...isbeingheldatTheNewYorkPalaceHotel.SteveWorland,Ph...provideanoverviewofAnadysanditsclinicaldevelopment...tationwillbesimultaneouslywebcastandcanbeaccessedo...
Breaking Medicine Technology:DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference 2Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2MessageSolution Enterprise Email Archive Named Top Exchange Archiving Solution by Leading Exchange Site MSExchange org 55476 1MessageSolution Enterprise Email Archive Named Top Exchange Archiving Solution by Leading Exchange Site MSExchange org 55476 2MessageSolution Enterprise Email Archive Named Top Exchange Archiving Solution by Leading Exchange Site MSExchange org 55476 3MessageSolution Enterprise Email Archive Named Top Exchange Archiving Solution by Leading Exchange Site MSExchange org 55476 4MessageSolution Enterprise Email Archive Named Top Exchange Archiving Solution by Leading Exchange Site MSExchange org 55476 5New York Personal Injury Attorney Defends Medical Malpractice 55474 1New York Personal Injury Attorney Defends Medical Malpractice 55474 2New York Personal Injury Attorney Defends Medical Malpractice 55474 3Mennen Medical Receives Frost 26amp 3B Sullivan 2009 European Patient Monitoring Technology Leadership Award 55472 1Mennen Medical Receives Frost 26amp 3B Sullivan 2009 European Patient Monitoring Technology Leadership Award 55472 2Mennen Medical Receives Frost 26amp 3B Sullivan 2009 European Patient Monitoring Technology Leadership Award 55472 3
... Clinical Research Relationships and Proven, Tra...Commercialization, SANTA CLARA, Calif., Aug. 18 ...ac diagnostic and services company, today,announce... president. Mr.,Renz will oversee the Company,s co...pment, client services, software development, and ...
...us Medical, Inc., the largest,privately held spina...ed,that the first FLEXUS(TM) Interspinous Spacers ...e Exemption ("IDE") recently granted to Globus by ...FLEXUS(TM) Spacer is placed with a unilateral appr...sruption to the surrounding musculature,and tissue...
Other Medicine Technology:Vincent W. Renz Joins NewCardio as President 2Vincent W. Renz Joins NewCardio as President 3Vincent W. Renz Joins NewCardio as President 4First FLEXUS(TM) Interspinous Spacer Surgeries for IDE Clinical Trial 2
(Date:11/26/2009)...le Dental (RTDental), a leading dental group pract... expansion of its services to include LUMINEERS by... , Durham, NC (PRWEB) ... that Dr. Doug Macmillan, an experienced LUMINEER...ced training seminar. RTDental’s ability to...
(Date:11/25/2009)...re-FirstCall/-- OnyxPharmaceuticals,Inc.(Nasdaq: ...toreventsinDecember: ,, ASHBriefing ,, ...ncipalinvestigatorswilldiscussdatapresentationssur...plemyeloma,asfeaturedatthe51stAmericanSocietyofHem...,LA.Theteleconferencewillbeginat9:00a.m.CT/10:00a....
(Date:11/25/2009)...wswire/--TheBlackAIDSInstituterecentlyheldBoardofD...010. ,, ThenewBoardMembersareahighlydiversegrou...e,governmenthealthprograms,editorial,andbusinessen...rsonalbackgroundsincludingbothheterosexualandgayBl...esentingmultipleagegroups. ,, (Photo: http://ww...
(Date:11/25/2009)...of a collaboration between UCLA engineers and phys...10 million Americans who suffer from peripheral ar... the arteries, peripheral arterial disease, or PAD...d arteries reduce blood flow to the limbs. The con...se, heart attack and stroke, and its progression c...
(Date:11/25/2009)... to overlook needed care, study finds , ,...s depression can worsen her child,s asthma, U.S. r...of 262 black mothers and their children found that...ms had more frequent asthma symptoms, while childr...ess frequent asthma symptoms. , The Johns Hopki...
Breaking Medicine News(10 mins):Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2Health News:Black AIDS Institute Announces 2010 Board Election Results 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Mom's Depression May Worsen Child's Asthma 2
...s been detected in Asia, the British government an...re sites for any evidence of bird flu. The dea...s, reservoirs and parks will be brought to the not... from the University of Hong Kong have detected a ...
...ptoms of schizophrenia can be relieved by music th... London conducted a study in 4 hospitals and found...ents when they were encouraged to express themselv...n people are fairly stable," said Dr Mike Crawford...
...today welcomed the Stern Review as a timely and au...mpact of climate change on the world’s human popul... now. Commissioned by the UK Government and p...ortant he has ever received. Dr Haikerwal sa...
...om umbilical cord blood stem cells for the first t...eed for animal experiments for drug testing. A...ize of a 1p coin, is just the initial phase of gen... association with experts from the U.S. The artifi...
...n's agency has launched the first online game in K... HIV and Aids. The game is named as "What woul...ough several different scenarios so that he import...Aids. Africa has the largest number of HIV inf...
...nfant’s risk of cot death or sudden infant death s...hat affect breathing and temperature control. // ...s who died of SIDS. The findings were published in...ocessing of the chemical called serotonin in the b...
Other Medicine News:Health News:A Timely Reminder Of Devastating Health Impact Of Climate Change 2Health News:Artificial Liver from Cord Blood Stem cells 2Health News:Brain stem Defects associated with SIDS 2
...ctious disease ELISA products make us a leader in ...er integration into the busy laboratory, our Infec...iability and run-to-run consistency. Our Infectiou...ssays for a wide range of serological assays inclu...
...ctious disease ELISA products make us a leader in ...er integration into the busy laboratory, our Infec...iability and run-to-run consistency. Our Infectiou...ssays for a wide range of serological assays inclu...
...ctious disease ELISA products make us a leader in ...er integration into the busy laboratory, our Infec...iability and run-to-run consistency. Our Infectiou...ssays for a wide range of serological assays inclu...
...ctious disease ELISA products make us a leader in ...er integration into the busy laboratory, our Infec...iability and run-to-run consistency. Our Infectiou...ssays for a wide range of serological assays inclu...
Medicine Products: